- ICH GCP
- EU klinikai vizsgálatok nyilvántartása
Legfrissebb próbák
EudraCT Number: 2004-004787-74 | Sponsor Protocol Number: Final protocol | Start Date: 2005-04-19 | ||||||
Sponsor Name: Royal Group of Hospitals Trust | ||||||||
Full Title: A double blind, prospective, randomised, controlled clinical trial to evaluate the effect of topical phenytoin, on healing, in diabetic foot ulcers. | ||||||||
Medical condition: Diabetes Mellitus and associated diabetic foot ulceration | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: GB (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-002069-19 | Sponsor Protocol Number: 333369-EPY-2003 | Start Date: 2005-04-19 | ||||||
Sponsor Name: Janssen-Cilag International NV | ||||||||
Full Title: A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects with Refractory Partial Seizures | ||||||||
Medical condition: Refractory partial epilepsy | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: GB (Completed) BE (Completed) ES (Ongoing) | ||||||||
Trial results: View results |
EudraCT Number: 2005-000043-28 | Sponsor Protocol Number: E05-001 | Start Date: 2005-04-19 | |||||||||||
Sponsor Name: ALEXION PHARMACEUTICALS INCORPORATED | |||||||||||||
Full Title: A Phase III, Open-Label, Extension Study of Eculizumab in Patients with Transfusion Dependent, Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Participated in the TRIUMPH (C04-001), SH... | |||||||||||||
Medical condition: paroxysmal nocturnal hemoglobinuria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IE (Completed) SE (Completed) DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004088-31 | Sponsor Protocol Number: B4Z-XM-LYDM | Start Date: 2005-04-19 | |||||||||||
Sponsor Name: Lilly S.A. | |||||||||||||
Full Title: A Randomized Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety of Atomoxetine up to 12 weeks in Newly Diagnosed Children and Adolescents Outpatients with Attention-Deficit/Hyp... | |||||||||||||
Medical condition: Attention-Deficit/Hyperactivity Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002724-17 | Sponsor Protocol Number: 02-NDOL-006 | Start Date: 2005-04-19 | ||||||
Sponsor Name: Fresenius Kabi Deutschland GmbH | ||||||||
Full Title: Efficacy of Neodolpasse™ in the treatment of postoperative pain: Morphine sparing effect during the first 24 hours postoperatively after unilateral total hip arthroplasty. | ||||||||
Medical condition: Patients with ASA classification I-III, female or male between 18 and 85 years of age, undergoing primary cementless unilateral total hip arthroplasty | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: AT (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2005-000872-41 | Sponsor Protocol Number: BGP-15-CLIN-IR01 | Start Date: 2005-04-19 | ||||||
Sponsor Name: N-Gene Research & Development Ltd. | ||||||||
Full Title: RANDOMIZED DOUBLE-BLIND, MULTIPLE DOSE, PLACEBO-CONTROLLED STUDY TO DETERMINE THE INSULIN SENSITIZING EFFECT OF BGP-15 IN PATIENTS WITH INSULIN RESISTANCE | ||||||||
Medical condition: The metabolic syndrome is characterized by central obesity, atherogenic dyslipidemia, insulin resistance or glucose intolerance; prothrombotic state; raised blood pressure, proinflammatory state | ||||||||
|
||||||||
Population Age: Adults | Gender: Male, Female | |||||||
Trial protocol: HU (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001403-35 | Sponsor Protocol Number: DOM2004 REDOX | Start Date: 2005-04-18 | ||||||
Sponsor Name: Doctor Pere Domingo | ||||||||
Full Title: Estudio abierto, multicéntrico y aleatorizado sobre la eficacia y seguridad de la reducción de dosis de estavudina en pacientes en tratamiento antirretroviral que incluye estavudina a dosis estánda... | ||||||||
Medical condition: AIDS | ||||||||
|
||||||||
Population Age: Adults | Gender: Male, Female | |||||||
Trial protocol: ES (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001124-20 | Sponsor Protocol Number: PCOS-5 | Start Date: 2005-04-18 | ||||||
Sponsor Name: Sigrun Kjøtrød | ||||||||
Full Title: Metformin treatment before IVF/ICSI in normal weight women with polycystic ovarian syndrome. A European, prospective, randomised, double blind, multicenter study. | ||||||||
Medical condition: Polycystic ovary syndrome (PCOS) is a disorder characterized by polycystic ovaries, oligo-amenorrhea and hyperandrogenism. It is the most common endocrine disorder in women of fertile age. PCOS wom... | ||||||||
|
||||||||
Population Age: Adults | Gender: Female | |||||||
Trial protocol: DK (Completed) SE (Completed) FI (Completed) GB (Prematurely Ended) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004415-29 | Sponsor Protocol Number: DU176b-PRT007 | Start Date: 2005-04-18 | |||||||||||
Sponsor Name: Daiichi Medical Research Inc | |||||||||||||
Full Title: A Phase IIa, multi-center, multi-national, open-label, dose ranging study of the efficacy, safety, and tolerability of oral DU-176b administered once or twice daily in the treatment of adult patien... | |||||||||||||
Medical condition: Prophylaxis of venous thromboembolism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005051-34 | Sponsor Protocol Number: 42-73-305 / WIL1-0305 | Start Date: 2005-04-18 | |||||||||||
Sponsor Name: LFB BIOTECHNOLOGIES | |||||||||||||
Full Title: Efficacy and safety study of vWF SD-35-DH (WILFACTIN) in children under 6 years of age | |||||||||||||
Medical condition: Von Willebrand disease | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |